467 related articles for article (PubMed ID: 26635725)
1. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
Viola D; Valerio L; Molinaro E; Agate L; Bottici V; Biagini A; Lorusso L; Cappagli V; Pieruzzi L; Giani C; Sabini E; Passannati P; Puleo L; Matrone A; Pontillo-Contillo B; Battaglia V; Mazzeo S; Vitti P; Elisei R
Endocr Relat Cancer; 2016 Apr; 23(4):R185-205. PubMed ID: 27207700
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies in thyroid cancer: an extensive review of the literature.
Bikas A; Vachhani S; Jensen K; Vasko V; Burman KD
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1299-1313. PubMed ID: 27367142
[TBL] [Abstract][Full Text] [Related]
5. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Raue F; Frank-Raue K
Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
[TBL] [Abstract][Full Text] [Related]
6. Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review.
Al-Jundi M; Thakur S; Gubbi S; Klubo-Gwiezdzinska J
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751138
[TBL] [Abstract][Full Text] [Related]
7. An update on clinical trials of targeted therapies in thyroid cancer.
Haraldsdottir S; Shah MH
Curr Opin Oncol; 2014 Jan; 26(1):36-44. PubMed ID: 24240178
[TBL] [Abstract][Full Text] [Related]
8. Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities.
Lorusso L; Cappagli V; Valerio L; Giani C; Viola D; Puleo L; Gambale C; Minaldi E; Campopiano MC; Matrone A; Bottici V; Agate L; Molinaro E; Elisei R
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803747
[TBL] [Abstract][Full Text] [Related]
9. An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer.
Yun KM; Cohen EEW
JCO Oncol Pract; 2024 Mar; ():OP2300747. PubMed ID: 38452309
[TBL] [Abstract][Full Text] [Related]
10. Molecular features of aggressive thyroid cancer.
Elia G; Patrizio A; Ragusa F; Paparo SR; Mazzi V; Balestri E; Botrini C; Rugani L; Benvenga S; Materazzi G; Spinelli C; Antonelli A; Fallahi P; Ferrari SM
Front Oncol; 2022; 12():1099280. PubMed ID: 36605433
[TBL] [Abstract][Full Text] [Related]
11. Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies.
Elia G; Ferrari SM; Ragusa F; Paparo SR; Mazzi V; Ulisse S; Benvenga S; Antonelli A; Fallahi P
Expert Opin Pharmacother; 2022 Apr; 23(5):599-610. PubMed ID: 35038965
[TBL] [Abstract][Full Text] [Related]
12. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Patrizio A; Paparo SR; Marone G; Galdiero MR; Guglielmi G; Foddis R; Cristaudo A; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():203-216. PubMed ID: 32569821
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
Zhang L; Feng Q; Wang J; Tan Z; Li Q; Ge M
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188928. PubMed ID: 37257629
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapy in Thyroid Cancer: State of the Art.
Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
[TBL] [Abstract][Full Text] [Related]
15. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapeutic approaches to advanced thyroid cancers.
Menefee ME; Smallridge RC; Bible KC
Am Soc Clin Oncol Educ Book; 2012; ():389-92. PubMed ID: 24451769
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied.
Ferrari SM; Ruffilli I; Centanni M; Virili C; Materazzi G; Alexopoulou M; Miccoli M; Antonelli A; Fallahi P
Recent Pat Anticancer Drug Discov; 2018; 13(2):201-208. PubMed ID: 29468981
[TBL] [Abstract][Full Text] [Related]
18. Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins RS; Jesus TT; Cardoso L; Soares P; Vinagre J
J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511745
[TBL] [Abstract][Full Text] [Related]
19. Effects and Role of Multikinase Inhibitors in Thyroid Cancer.
Laursen R; Wehland M; Kopp S; Pietsch J; Infanger M; Grosse J; Grimm D
Curr Pharm Des; 2016; 22(39):5915-5926. PubMed ID: 27306093
[TBL] [Abstract][Full Text] [Related]
20. Personalization of targeted therapy in advanced thyroid cancer.
Fallahi P; Ferrari SM; Mazzi V; Vita R; Benvenga S; Antonelli A
Curr Genomics; 2014 Jun; 15(3):190-202. PubMed ID: 24955027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
